Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
News|Articles|October 31, 2025
Pharmaceutical Executive Presents: Most Favored Nation Order - How Trump Is Disrupting Pharma
Author(s)PharmExec Staff
Listen
0:00 / 0:00
Key Takeaways
- The MFN model, DTC channels, and tariffs are set to transform drug market dynamics, affecting key stakeholders like payers and manufacturers.
- The webinar will evaluate if MFN is a sustainable reform or merely a political issue, impacting future healthcare policies.
Join us for a premium webinar on November 4, 2025!
Advertisement
With Most Favored Nation (MFN) and the emergence of the direct-to-consumer (DTC) model and potential tariffs, traditional roles of payers, pharmacy benefit managers, manufacturers, and 340B hospitals would be fundamentally reshaped.
Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets
On November 4, this exclusive webinar will cut through the political noise and provide a critical, operational analysis of these seismic shifts. We will explore whether MFN is a foundation for permanent reform or simply a political flashpoint, how the proposed mandatory payment models GLOBE and GUARD fit into the future, and what the real-world impact of tariffs and DTC channels will be.
Advertisement
Related to this article
New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.
While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on PharmExec
1
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
2
Pharming CEO Fabrice Chouraqui Steps Down Amid Strategic Disagreement with Board
3
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5